Balyasny Asset Management
XGN icon

Balyasny Asset Management’s Exagen XGN Stock Holding History

Balyasny Asset Management’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.39M Sell
796,632
-122,555
-13% -$474K ﹤0.01% 1704
2025
Q4 		$5.59M Buy
919,187
+195,759
+27% +$1.78M 0.01% 1337
2025
Q3 		$7.95M Buy
723,428
+4,646
+0.6% +$41.1K 0.01% 1173
2025
Q2 		$5.02M Buy
+718,782
New +$4.37M 0.01% 1295

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Balyasny Asset Management's XGN Position: Q1 2026 in Review

Balyasny Asset Management reduced its Exagen (XGN) stake by 13% in Q1 2026, selling an estimated $474K and leaving 796,632 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1704.

Balyasny Asset Management first reported a position in XGN in Q2 2025 and has held it in 4 quarters since. The position peaked at $7.95M in Q3 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Balyasny Asset Management held 796,632 shares of Exagen worth $2.39M as of Q1 2026.
  • Balyasny Asset Management sold 122,555 Exagen shares in Q1 2026, an estimated $474K.
  • Exagen made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1704 holding.
  • Balyasny Asset Management first reported a position in Exagen in Q2 2025 and has held it in 4 quarters since.
  • Balyasny Asset Management's Exagen position peaked at $7.95M in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.